Full Access To HCV Drugs Would Save Money Long-Term, Study Finds
This article was originally published in The Pink Sheet Daily
Executive Summary
Restricting coverage to the sickest HCV patients saves individual Medicaid programs money in the short-term, a study by ISPOR finds, but increases costs for Medicare in the longer-term.
You may also be interested in...
Gilead Sees Prospects For Declining HCV Revenues To Stabilize
A confluence of factors, including a higher proportion of patients covered by public payers, has caused Gilead's powerhouse hepatitis C franchise to slow down and now begin showing signs of decline.
Merck Suit Against Medicare: Constitutional Arguments Are Scathing, But Are They Persuasive?
A suit designed to test the limits of the protections against judicial review that are embedded in the IRA could have more traction, some legal scholars suggest.